| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.33 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
A Regulamentação Europeia do Medicamento representa uma Ć”rea de extrema importĆ¢ncia, tanto para as instituiƧƵes europeias como, para os cidadĆ£os e profissionais de saĆŗde europeus que diariamente lidam com os resultados desta regulação. Na Europa, a regulamentação foi impulsionada por uma sĆ©rie de eventos adversos resultantes da utilização de medicamentos que nĆ£o haviam sido previamente analisados. Estes eventos, criaram a perceção de que, devido as caracterĆsticas Ćŗnicas deste tipo de produto, deveria existir um quadro regulamentar que implemente a obrigatoriedade da aprovação, por uma entidade competente, previamente Ć entrada no mercado. A garantia de qualidade, seguranƧa, eficĆ”cia e conformidade com as diretrizes estabelecidas Ć© hoje um elemento obrigatório no processo de desenvolvimento e comercialização das vĆ”rias especialidades farmacĆŖuticas. Esta era inicia-se com a aprovação da Diretiva 65/65/EEC e subsequentes diretivas e regulamentos que expandem o campo de ação desta. Com o avanƧo do processo de harmonização e com o objetivo de estabelecer uma Europa do medicamento com um mercado Ćŗnico, em que exista a livre circulação de bens, informação e conhecimento surge a necessidade de criar uma AgĆŖncia Europeia que coordene a ação das vĆ”rias autoridades nacionais competentes. Estas, criam uma rede de governance em que a polĆtica do medicamento Ć© estabelecida em diĆ”logo e com intervenção das autoridades nacionais competentes de cada Estado-Membro. Para a correta compreensĆ£o do quadro geral do medicamento no panorama europeu torna-se necessĆ”rio definir e estudar de que forma se opera a delegação de poderes sobre a polĆtica do medicamento em cada Estado. Apresenta-se como um quadro que Ć© elemento central do sucesso de polĆticas impactadas pelo do elevado valor económico e devido ao papel que desempenha na persecução de uma adequada polĆtica de saĆŗde, estimulando o acesso ao medicamento e o reforƧo da saĆŗde publica. Deste modo, conseguimos ainda definir um modelo visual de organização de cada uma das agĆŖncias permitindo o seu melhor estudo e compreensĆ£o.
The European regulation of medicines is an extremely important area for both the European institutions and for European citizens and healthcare professionals who deal with the results of this regulation daily. In Europe, a regulation was driven by several adverse events from the use of medicines that had not been analyzed in advance. These events have created the perception that, resulting from the unique characteristics of this type of product, there should be a guideline framework, implementing the requirements for approval by a competent authority before market entry. Quality, safety, efficacy, and compliance with the guidelines are now a compulsory element in the development and marketing of the various pharmaceutical products. These notions begin with the implementation of Directive 65/65/EEC and the consequent directives and regulations that expand its action. With the advance of this project and aims to establish in Europe, a single market for medicines, in which goods, information, and knowledge are shared, there is a need to set up a European Agency to coordinate the action of the various national agents. These agencies create a network of governance in which the medicine policy is established based on the intervention of the competent national authorities of each Member State. To properly understand medicines in the European landscape, it is necessary to define and study how the delegation of powers over the policy of the medicine, in each political nation of the European Union, which is presented as a central element of the success of a country derived from the high monetary value that it is moving and because of its role in pursuing a health policy that safeguards the financial well-being of a country while stimulating access to the medicine and public health. In this way, it is possible to define a visual model for the organization of each agency, allowing for its best study and understanding.
The European regulation of medicines is an extremely important area for both the European institutions and for European citizens and healthcare professionals who deal with the results of this regulation daily. In Europe, a regulation was driven by several adverse events from the use of medicines that had not been analyzed in advance. These events have created the perception that, resulting from the unique characteristics of this type of product, there should be a guideline framework, implementing the requirements for approval by a competent authority before market entry. Quality, safety, efficacy, and compliance with the guidelines are now a compulsory element in the development and marketing of the various pharmaceutical products. These notions begin with the implementation of Directive 65/65/EEC and the consequent directives and regulations that expand its action. With the advance of this project and aims to establish in Europe, a single market for medicines, in which goods, information, and knowledge are shared, there is a need to set up a European Agency to coordinate the action of the various national agents. These agencies create a network of governance in which the medicine policy is established based on the intervention of the competent national authorities of each Member State. To properly understand medicines in the European landscape, it is necessary to define and study how the delegation of powers over the policy of the medicine, in each political nation of the European Union, which is presented as a central element of the success of a country derived from the high monetary value that it is moving and because of its role in pursuing a health policy that safeguards the financial well-being of a country while stimulating access to the medicine and public health. In this way, it is possible to define a visual model for the organization of each agency, allowing for its best study and understanding.
Descrição
Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, 2020, Universidade de Lisboa, Faculdade de FarmÔcia.
Palavras-chave
Regulamentação do medicamento Agência Europeia do Medicamento Autoridades nacionais competentes Governança Harmonização Mestrado integrado - 2020
